| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2083298 | European Journal of Pharmaceutics and Biopharmaceutics | 2015 | 9 Pages |
Abstract
- Cx43 MP was successfully loaded into PLGA nano- and microparticles.
- In vitro studies revealed a triphasic pattern with sustained release over months.
- Retinal ischaemia-reperfusion injury was used for in vivo studies.
- Intravitreally delivered Cx43 MP reduced Cx43 levels and promoted RGC survival.
- Nps-Cx43 MP showed the most promising results due to sustained peptide release.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
Ying-Shan Chen, Colin R. Green, Kailun Wang, Helen V. Danesh-Meyer, Ilva D. Rupenthal,